Huang Y, Chen J, Pang S, Yu K, Kan H, Shao I
J Robot Surg. 2025; 19(1):114.
PMID: 40072726
DOI: 10.1007/s11701-025-02253-0.
Barroso T, Monteiro C, Patel V, Goncalves L, Sousa A, Lopes Bras R
Cureus. 2025; 17(2):e78493.
PMID: 40051948
PMC: 11884503.
DOI: 10.7759/cureus.78493.
da Silva I, de Amorim L, Piredda G, Mass-Lindenbaum M, de Moraes F, Freitas P
Clin Transl Oncol. 2025; .
PMID: 39987332
DOI: 10.1007/s12094-025-03851-y.
Ali A, Elumalai T, Venkatesulu B, Hekman L, Mistry H, Sachdeva A
BMJ Oncol. 2025; 3(1):e000193.
PMID: 39886173
PMC: 11234997.
DOI: 10.1136/bmjonc-2023-000193.
Badrane I, Castello A, Brunelli M, Cittanti C, Adamantiadis S, Bagni I
Biomolecules. 2025; 15(1).
PMID: 39858412
PMC: 11762331.
DOI: 10.3390/biom15010017.
A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China.
Gratzke C, Aggarwal H, Kim J, Chaignaud H, Oskar S
Eur Urol Open Sci. 2025; 71():148-155.
PMID: 39845739
PMC: 11751505.
DOI: 10.1016/j.euros.2024.07.113.
Initial clinical experience with [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort of the SPLASH trial.
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S
Front Oncol. 2025; 14():1483953.
PMID: 39839782
PMC: 11745944.
DOI: 10.3389/fonc.2024.1483953.
Ascertaining provider-level implicit bias in electronic health records with rules-based natural language processing: A pilot study in the case of prostate cancer.
Ramaswamy A, Hung M, Pelt J, Iranmahboub P, Calderon L, Scherr I
PLoS One. 2025; 19(12):e0314989.
PMID: 39775249
PMC: 11684669.
DOI: 10.1371/journal.pone.0314989.
Luteinizing hormone-releasing hormone receptor agonists and antagonists in prostate cancer: effects on long-term survival and combined therapy with next-generation hormonal agents.
Zhao J, Chen J, Sun G, Shen P, Zeng H
Cancer Biol Med. 2024; 21(11).
PMID: 39718161
PMC: 11667785.
DOI: 10.20892/j.issn.2095-3941.2024.0139.
Construction for the predictive model of quality of life in patients after robot-assisted radical prostatectomy: a cohort study.
Wu Y, Wang J, Zhou X, Zhu W, Su X, Zeng B
Int J Med Sci. 2024; 21(15):2981-2991.
PMID: 39628687
PMC: 11610334.
DOI: 10.7150/ijms.100845.
Time to Next Systemic Therapy After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Castrate-Resistant Prostate Cancer.
Eule C, Candelario N, Nath S, Robin T
Adv Radiat Oncol. 2024; 9(12):101655.
PMID: 39620140
PMC: 11605447.
DOI: 10.1016/j.adro.2024.101655.
Theranostics Nuclear Medicine in Prostate Cancer.
Lima H, Etchebehere M, Bogoni M, Torricelli C, Nogueira-Lima E, Deflon V
Pharmaceuticals (Basel). 2024; 17(11).
PMID: 39598394
PMC: 11597825.
DOI: 10.3390/ph17111483.
Clinical characteristics and treatment of patients with small cell prostate cancer: analysis of a real-world cohort from an oncology database.
Eule C, Warren A, Kuna E, Robin T, Gershman B, Kim S
Prostate Cancer Prostatic Dis. 2024; .
PMID: 39572637
DOI: 10.1038/s41391-024-00914-z.
Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
Raval A, Chen S, Littleton N, Constantinovici N, Goebell P
BJU Int. 2024; 135(3):408-421.
PMID: 39530232
PMC: 11842892.
DOI: 10.1111/bju.16577.
Compatibility of hypokalaemia caused by low-dose prednisolone plus abiraterone acetate therapy for metastatic castration-resistant prostate cancer.
Torii S, Torii-Goto A, Tanizawa T, Sakakibara T, Oguri R, Nagase H
J Pharm Health Care Sci. 2024; 10(1):72.
PMID: 39529147
PMC: 11552156.
DOI: 10.1186/s40780-024-00391-5.
Clinical Responses to Prostate-specific Membrane Antigen Radioguided Salvage Lymphadenectomy for Prostate Cancer Recurrence: Results from a Prospective Exploratory Trial.
Weiner A, Ells Z, Meyer C, Dahlbom M, Sennung D, Varughese D
Eur Urol Open Sci. 2024; 70:36-42.
PMID: 39483519
PMC: 11525452.
DOI: 10.1016/j.euros.2024.09.004.
Identifying the best candidate for focal therapy: a comprehensive review.
Ghoreifi A, Gomella L, Hu J, Konety B, Lunelli L, Rastinehad A
Prostate Cancer Prostatic Dis. 2024; .
PMID: 39443815
DOI: 10.1038/s41391-024-00907-y.
Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.
Yi Z, Li H, Li M, Hu J, Cai Z, Liu Z
World J Urol. 2024; 42(1):581.
PMID: 39419868
DOI: 10.1007/s00345-024-05286-6.
N-Linked Fucosylated Glycans Are Biomarkers for Prostate Cancer with a Neuroendocrine and Metastatic Phenotype.
Ippolito J, Hartig J, Bejar K, Nakhoul H, Sehn J, Weimholt C
Mol Cancer Res. 2024; 23(1):59-70.
PMID: 39417716
PMC: 11694069.
DOI: 10.1158/1541-7786.MCR-24-0660.
Prognostic value of [F]FDG PET/CT in metastatic hormone-sensitive prostate cancer at initial diagnosis: a retrospective cohort study.
Li A, Shen K, Ji Y, Zhang W, Liu B, Su R
Ann Med. 2024; 56(1):2411017.
PMID: 39392016
PMC: 11485890.
DOI: 10.1080/07853890.2024.2411017.
